A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone
A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone
This study is a multicenter, open-label, observational, postmarketing surveillance study of
 Genentech growth hormone (GH) products in the treatment of girls with Turner syndrome in the
 United States and Canada.
Inclusion Criteria:

 -  Are girls with Turner syndrome who are being or will be treated with Nutropin,
 Nutropin AQ, or Protropin

 -  Are willing to keep follow-up appointments throughout study participation

 -  Are girls with Turner syndrome who have submitted Form 4 upon discontinuation and may
 also submit Form 9

 Exclusion Criteria:

 -  Have Noonan syndrome

 -  Subjects treated within the last 6 months with a non-Genentech GH preparation

 -  Have closed epiphyses prior to NCGS enrollment

 -  Have active neoplasia